Thymosin Alpha-1 — 5 mg

Thymosin alpha-1 is a peptide originally identified in thymus-derived material. Its synthetic version is known as thymalfasin. Umbrella describes effects on T-cell maturation and innate immune signaling and relates the product to hepatitis and immune-adjuvant research. Mechanistic discussions include immune-cell activation and pathways associated with antigen presentation, rather than a simple, universal increase in every aspect of immunity.

Clinical investigators have explored whether this immunomodulatory activity can improve outcomes in severe infection. The ETASS trial reported an improvement in a monocyte immune-function marker and a possible survival signal, while acknowledging the need for confirmation. A later large placebo-controlled phase 3 sepsis trial did not demonstrate a reduction in its primary mortality outcome. Both reports belong in a description of what the literature says: immune-function changes and patient survival are different endpoints. Thus, the research themes include immune regulation, infection-associated immune suppression, and adjunctive therapy, with results tied to the specific study. The seller’s research vial should not be conflated with a clinical thymalfasin formulation.